Posted by Michael Wonder on 05 Feb 2025
Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer (final guidance)
5 February 2025 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adjuvant treatment of adults with resected non-small-cell lung cancer.
Pembrolizumab is recommended as an option for the adjuvant treatment of adults with non-small-cell lung cancer with a high risk of recurrence after complete resection and platinum-based chemotherapy. Pembrolizumab is only recommended if MSD provides it according to the commercial arrangement.
